

# Elizabeth P Henske

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1426859/publications.pdf>

Version: 2024-02-01

61  
papers

12,671  
citations

201575

27  
h-index

128225

60  
g-index

66  
all docs

66  
docs citations

66  
times ranked

27046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
3	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	7.7	665
4	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
5	Unjamming and cell shape in the asthmatic airway epithelium. <i>Nature Materials</i> , 2015, 14, 1040-1048.	13.3	484
6	Tuberous sclerosis complex. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16035.	18.1	473
7	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017, 31, 820-832.e3.	7.7	433
8	Lymphangioliomyomatosis – a wolf in sheep’s clothing. <i>Journal of Clinical Investigation</i> , 2012, 122, 3807-3816.	3.9	258
9	Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. <i>Lancet</i> , The, 2003, 361, 1348-1349.	6.3	196
10	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. <i>Journal of Experimental Medicine</i> , 2014, 211, 2249-2263.	4.2	170
11	Lymphangioliomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1210-1212.	2.5	168
12	Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioliomyomatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	156
13	Aggressive variants of chromophobe renal cell carcinoma. <i>Cancer</i> , 1996, 78, 1756-1761.	2.0	100
14	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , 2016, 12, e1006242.	1.5	93
15	Tumour predisposition and cancer syndromes as models to study gene–environment interactions. <i>Nature Reviews Cancer</i> , 2020, 20, 533-549.	12.8	93
16	Renal disease in tuberous sclerosis complex: pathogenesis and therapy. <i>Nature Reviews Nephrology</i> , 2018, 14, 704-716.	4.1	83
17	New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. <i>Journal of Pathology</i> , 2017, 241, 219-225.	2.1	67
18	Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. <i>Physiological Reports</i> , 2014, 2, e12107.	0.7	53

#	ARTICLE	IF	CITATIONS
19	TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism. <i>Nature Communications</i> , 2021, 12, 4245.	5.8	52
20	p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. <i>Cancer Research</i> , 2017, 77, 3255-3267.	0.4	49
21	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	49
22	Mechanisms of pulmonary cyst pathogenesis in Birt-Hogg-Dube syndrome: The stretch hypothesis. <i>Seminars in Cell and Developmental Biology</i> , 2016, 52, 47-52.	2.3	48
23	Sirolimus and Autophagy Inhibition in Lymphangiomyomatosis. <i>Chest</i> , 2017, 151, 1302-1310.	0.4	46
24	The Genetics of Pneumothorax. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1344-1357.	2.5	45
25	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , 2016, 60, 1-12.	1.0	43
26	Renal Cell Carcinoma in Tuberous Sclerosis Complex. <i>Genes</i> , 2021, 12, 1585.	1.0	33
27	Metabolic reprogramming in polycystic kidney disease. <i>Nature Medicine</i> , 2013, 19, 407-409.	15.2	32
28	Tuberous Sclerosis Complex 2 Loss Increases Lysophosphatidylcholine Synthesis in Lymphangiomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 33-41.	1.4	30
29	Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangiomyomatosis. <i>Cancer Research</i> , 2017, 77, 5491-5502.	0.4	29
30	Familial pneumothorax: towards precision medicine. <i>Thorax</i> , 2018, 73, 270-276.	2.7	26
31	Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2-Related Tumor Related to Lymphangiomyomatosis. <i>American Journal of Pathology</i> , 2016, 186, 1825-1836.	1.9	24
32	Emerging biomarkers of lymphangiomyomatosis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 95-102.	1.0	22
33	The TSC Complex-mTORC1 Axis: From Lysosomes to Stress Granules and Back. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751892.	1.8	22
34	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. <i>Journal of Experimental Medicine</i> , 2019, 216, 2635-2652.	4.2	20
35	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. <i>Oncotarget</i> , 2017, 8, 64714-64727.	0.8	18
36	Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F279-F283.	1.3	17

#	ARTICLE	IF	CITATIONS
37	Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. <i>Cancer Research</i> , 2017, 77, 1492-1502.	0.4	17
38	Immunotherapy for Lymphangioliomyomatosis and Tuberous Sclerosis. <i>Chest</i> , 2019, 156, 1062-1067.	0.4	15
39	A genome-wide association study implicates <i>NR2F2</i> in lymphangioliomyomatosis pathogenesis. <i>European Respiratory Journal</i> , 2019, 53, 1900329.	3.1	14
40	MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of <i>CYR61</i> . <i>Oncogene</i> , 2021, 40, 112-126.	2.6	14
41	Kidney intercalated cells and the transcription factor <i>FOXi1</i> drive cystogenesis in tuberous sclerosis complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
42	Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioliomyomatosis. <i>Chest</i> , 2018, 154, 1070-1082.	0.4	13
43	Interleukin-6 mediates <i>PSAT1</i> expression and serine metabolism in <i>TSC2</i> -deficient cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	13
44	Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
45	Mesenchymal folliculin is required for alveolar development: implications for cystic lung disease in Birt-Hogg-Dub� syndrome. <i>Thorax</i> , 2020, 75, 486-493.	2.7	12
46	Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via <i>NPC1</i> and <i>LDL-R</i> . <i>Oncotarget</i> , 2017, 8, 38099-38112.	0.8	12
47	Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in <i>TSC2</i> -deficient cells by downregulating tumor suppressor retinoic acid receptor � <sup>2</sup> ( <i>RAR�<sup>2</sup></i> ). <i>Oncogene</i> , 2019, 38, 7367-7383.	2.6	11
48	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. <i>Oncotarget</i> , 2017, 8, 17628-17642.	0.8	11
49	Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. <i>Cancer Research</i> , 2021, 81, 2086-2100.	0.4	8
50	Celecoxib in lymphangioliomyomatosis: results of a phase I clinical trial. <i>European Respiratory Journal</i> , 2020, 55, 1902370.	3.1	7
51	Targeted deletion of <i>Tsc1</i> causes fatal cardiomyocyte hyperplasia independently of afterload. <i>Cardiovascular Pathology</i> , 2015, 24, 80-93.	0.7	6
52	mTORC1 is a mechanosensor that regulates surfactant function and lung compliance during ventilator-induced lung injury. <i>JCI Insight</i> , 2021, 6, .	2.3	6
53	Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis-associated lymphangioliomyomatosis. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 72.	1.2	5
54	Generalised mosaicism for <i>TSC2</i> mutation in isolated lymphangioliomyomatosis. <i>European Respiratory Journal</i> , 2019, 54, 1900938.	3.1	5

#	ARTICLE	IF	CITATIONS
55	Chromophobe renal cell carcinoma: New genetic and metabolic insights. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 678-681.	0.8	4
56	Seventh BHD international symposium: recent scientific and clinical advancement. <i>Oncotarget</i> , 2022, 13, 173-181.	0.8	4
57	Modeling tuberous sclerosis with organoids. <i>Science</i> , 2022, 375, 382-383.	6.0	4
58	The Codon 72 <i>TP53</i> Polymorphism Contributes to TSC Tumorigenesis through the Notch/Nodal Axis. <i>Molecular Cancer Research</i> , 2019, 17, 1639-1651.	1.5	2
59	Getting to the finish line with mTORC1-targeted therapy. <i>Journal of Clinical Investigation</i> , 2012, 122, 1970-1972.	3.9	2
60	ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells. <i>Life Science Alliance</i> , 2022, 5, e202201369.	1.3	2
61	Vitamin D binding protein: a new biomarker of disease severity in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2018, 52, 1801886.	3.1	0